Skip to content

Edgewise 制药

US · EWTX #2209 按市值排名 上市于 2021
37.19 -1.01 -2.64%
实时 - 追踪5344个代码 - 心跳于567秒前 · 2026-10-16 19:30

✦ 量化股权信号 计算方式说明

减持
  • 最近一期（2026/Q3）披露持股的机构数量减少了3家。
  • 机构持股总比例下降了1.2个百分点。

机构持股

机构持股比例
111.09% -1.23pp
机构数量
281 -3
数据截至
2026/Q3 较上一报告期

持股变动 vs 资金流向

方向一致

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund45.42%
VC/PE Fund35.91%
Hedge Fund23.86%
Public Company4.25%
Government Pension Fund0.59%
Sovereign Wealth Fund0.48%
Private Company0.38%
Individual/Insider0.19%
Family Office/Trust0.11%

主要股东 截至 2026-06-30

OrbiMed Advisors LLC 14.29% · 15.52M 股
Paradigm Biocapital Advisors LP 9.41% · 10.22M 股
RA Capital Management, L.P. 7.73% · 8.39M 股
BlackRock 6.08% · 6.61M 股
Janus Henderson Group plc 5.59% · 6.08M 股
FMR 5.05% · 5.49M 股
Novo Holdings A/S 4.93% · 5.35M 股
Driehaus Capital Management LLC 4.35% · 4.73M 股
Vanguard Capital Management, LLC 4.06% · 4.41M 股
Perceptive Advisors LLC 4.03% · 4.37M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 35次买入 · 15次卖出

姓名职务持股比例
OrbiMed Advisors LLC -- 14.29%
Kevin Koch Chief Executive Officer 0.05%
Behrad Derakhshan Chief Business Officer 0.03%
Alan Russell Co-Founder, Chief Scientific Officer & Director 0.03%
Jonathan Fox Independent Director 0.02%
Badreddin Edris Co-Founder & Independent Director 0.02%
John Moore General Counsel 0.02%
Jonathan Root Independent Director 0.01%
Joanne Donovan Chief Medical Officer 0.01%
Robert Blaustein Chief Development Officer 0.01%

内部人交易 最近的 Form 4 申报记录

日期姓名职务类型股数价格
2026-09-30 Jonathan Fox Independent Director Other Acquisition +308 --
2026-08-12 Joanne Donovan Chief Medical Officer Derivative Exercise and Sale -9,441 $43.41–44.52
2026-08-11 Kevin Koch Chief Executive Officer Derivative Exercise and Sale -17,971 $43.64–44.33
2026-08-11 Kevin Koch Chief Executive Officer Other Derivative Acquisition +100,000 --
2026-08-11 Kevin Koch Chief Executive Officer Other Derivative Acquisition +200,000 $43.56
2026-08-11 Kevin Koch Chief Executive Officer Derivative Exercise and Retained +21,873 --
2026-08-11 John Moore General Counsel Derivative Exercise and Sale -5,016 $43.80–44.50
2026-08-11 John Moore General Counsel Other Derivative Acquisition +32,500 --
2026-08-11 John Moore General Counsel Other Derivative Acquisition +65,000 $43.56
2026-08-11 John Moore General Counsel Derivative Exercise and Retained +7,483 --
2026-08-11 Joanne Donovan Chief Medical Officer Other Derivative Acquisition +32,500 --
2026-08-11 Joanne Donovan Chief Medical Officer Other Derivative Acquisition +65,000 $43.56
2026-08-11 Joanne Donovan Chief Medical Officer Derivative Exercise and Retained +3,371 --
2026-08-11 Behrad Derakhshan Chief Business Officer Derivative Exercise and Sale -5,100 $43.70–44.50
2026-08-11 Behrad Derakhshan Chief Business Officer Other Derivative Acquisition +50,000 --
2026-08-11 Behrad Derakhshan Chief Business Officer Other Derivative Acquisition +100,000 $43.56
2026-08-11 Behrad Derakhshan Chief Business Officer Derivative Exercise and Retained +8,181 --
2026-08-11 Michael Nofi Chief Financial Officer Other Derivative Acquisition +24,375 --
2026-08-11 Michael Nofi Chief Financial Officer Other Derivative Acquisition +48,750 $43.56
2026-08-11 Alan Russell Co-Founder, Chief Scientific Officer & Director Derivative Exercise and Sale -5,901 $43.68–44.46

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 19:30:05 · 仅供参考，不构成投资建议，也未考虑您的具体情况。

Edgewise 制药 讨论区 0 条评论

发表评论